Reply to H.L. McArthur et al.
Dana-Farber Cancer Institute, Boston, MA.
Ines
I
Vaz-Luis
Dana-Farber Cancer Institute, Boston, MA Nancy_Lin@dfci.harvard.edu.
Nancy U
NU
Lin
D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry* / Q000188:drug therapy* / Q000473:pathology*; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000737:chemistry* / Q000188:drug therapy*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*
D061067:Antibodies, Monoclonal, Humanized; D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases